FACSIMILE TRANSMISSION SHEET

D. PETER HOCHBERG CO., L.P.A.
ATTORNEYS AT LAW
1940 EAST 6TH STREET
CLEVELAND, OHIO 44114

Telephone: (216) 771-3800 / Facsimile: (216) 771-3804 / e-mail: dphochberg@aol.com

TO: Ms. Isis Ghali FAX NO: (703) 872-9306

FROM: Peter Hochberg DATE: June 7, 2002

NUMBER OF PAGES (INCLUDING THIS COVER SHEET: 3

MESSAGE Re: U.S.S. No. 09/720,287
Filed: May 10, 2001
Our Ref: RO0208US (#90568)

Pursuant to our discussion today, I have attached the page from the applicaton with the original claims.

CLAIMS

1. Transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients which is attached to said backing layer and prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino-containing polymer.

2. Transdermal therapeutic system according to Claim 1, characterized in that the crystallization inhibitor is selected from polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, in particular in a molar ratio of 1:2:1, polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, polyamines and polyglucosamines.

3. Transdermal therapeutic system according to either of Claims 1 and 2, characterized in that the reservoir comprises one or more crystallization inhibitors in a proportion of from 0.05-30% by weight.

4. Transdermal therapeutic system according to one or more of Claims 1 - 3, characterized in that the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, preferably from 1:3 to 1:7, and in an overall concentration of up to 25% by weight.

5. Transdermal therapeutic system according to one or more of Claims 1 - 4, characterized in that the reservoir includes a constituent from the group of ageing inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizer being used in a concentration of 0-5% by weight

and the ageing inhibitor in a concentration of 0.1-2% by weight.

6. Transdermal therapeutic system according to one or more of Claims 1 - 5, characterized in that the pressure-sensitive adhesive is a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive or a UV-crosslinkable adhesive.

7. Transdermal therapeutic system according to one or more of Claims 1 - 6, characterized in that the reservoir consists of two or more layers.

8. Transdermal therapeutic system according to one or more of Claims 1 - 7, characterized in that the reservoir has a layer thickness of 0.02 mm-0.500 mm, preferably 0.030-0.200 mm.

9. Transdermal therapeutic system according to one or more of Claims 1 - 8, characterized in that the reservoir is provided with an additional pressure-sensitive adhesive layer and/or with a pressure-sensitive adhesive margin.

10. Use of the transdermal therapeutic system corresponding to one or more of Claims 1-9 for therapeutic applications in human medicine.